Cook MyoSite
Quick facts
Phase 3 pipeline
- AMDC-USR (iltamiocel) · Cardiovascular
AMDC-USR (iltamiocel) is an autologous skeletal myoblast cell therapy that regenerates damaged heart muscle tissue following myocardial infarction.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Cook MyoSite
What is Cook MyoSite's pipeline?
Cook MyoSite has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include AMDC-USR (iltamiocel).
Related
- Sector hub: All tracked pharma companies